Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: KM who wrote (768)	8/25/1999 2:52:00 AM
From: Daniel Levy	Read Replies (1) \| Respond to of 900

As with everything, there's politics involved. I hope Dr Bafort's information on the trials is accurate. Doxo is a very toxic drug, but also extremely valuable in therapy. Anything that can be done to mitigate its toxicity will be very warmly greeted by those treating cancer patients. (And hopefully by the market.)

To: KM who wrote (768)	8/25/1999 3:49:00 PM
From: Cheeseburger	Read Replies (1) \| Respond to of 900

Hey KM, you knucklehead. Sept. 16th is the day the FDA's panel of experts -- ODAC -- convene in some Maryland Hillbilly Hotel to review Evacet data presented by Liposome and the FDA. After hearing both sides, the panel will vote on whether the FDA should or should not clear Evacet for marketing -- the vote usually happens by 3:30 p.m. The FDA isn't bound to its panel's recommendations, but it usually follows its direction. Either way, the approval (or rejection) will take at least six weeks from Sept. 16th.